Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 518 across all filing types
Latest filing 2023-01-13 Report Publication Anno…
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Zatwierdzenie prospektu Emitenta przez KNF - Content (PL)
Report Publication Announcement Classification · 99% confidence The document is a short announcement (1302 characters) from the Management Board of Scope Fluidics S.A. (Emitent) stating that the Polish Financial Supervision Authority (KNF) approved the company's Prospectus on January 12, 2023. The text explicitly mentions that the Prospectus has been published and will be available on the company's website and the investment firm's website. According to Rule #2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a formal document (like a Prospectus, which is related to capital/financing) should be classified as a Report Publication Announcement (RPA) rather than the underlying document type itself. While the content relates to capital structure changes (CAP), the *action* described is the announcement of the publication of the required regulatory document (the Prospectus). Therefore, RPA is the most appropriate classification based on the document's nature and length.
2023-01-13 Polish
Złożenie wniosku do GPW o dopuszczenie i wprowadzenie akcji Emitenta do obrotu na rynku regulowanym GPW oraz o wykluczenie akcji Emitenta z obrotu na NewConnect - Content (PL)
Share Issue/Capital Change Classification · 99% confidence The document text, written in Polish, announces that the Issuer (Scope Fluidics S.A.) submitted an application to the Warsaw Stock Exchange (GPW) on January 13, 2023, to admit and introduce 2,686,205 shares (Series A through H) to trading on the regulated market and simultaneously requested their exclusion from the NewConnect alternative trading system. It also mentions that the legally binding document for this process is the Prospectus approved by the Polish Financial Supervision Authority (KNF) on January 12, 2023, and provides links where the Prospectus was made public. This action—applying for admission to a regulated market and delisting from an alternative market—is a significant corporate action related to capital structure and listing status. Since the document is an announcement about the application process and references the official Prospectus (which is a financing/capital document), it best fits the 'Capital/Financing Update' category (CAP). It is not a full report, an earnings release, or a standard regulatory filing (RNS), but a specific announcement about a capital market move.
2023-01-13 Polish
Zawarcie umowy najmu - Content (PL)
Regulatory Filings Classification · 100% confidence The document text is very short (525 characters) and describes a specific operational/business event: signing a lease agreement for new premises where laboratory space will be set up for future projects. This is not a standard regulatory filing like 10-K, IR, or ER. It relates to the company's operational setup and future plans, but it doesn't fit neatly into M&A (TAR), Financing (CAP), or Director's Dealing (DIRS). Since it is a specific, non-standard announcement concerning business operations and future facilities, and it doesn't match any of the highly specific categories (like AGM, Dividend, Audit, etc.), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory announcements.
2022-11-16 Polish
Otrzymanie wstrzymanej części Ceny Nabycia 100% udziałów Curiosity Diagnostics sp. z o.o. - Content (PL)
Capital/Financing Update Classification · 95% confidence The document text is a short announcement (1044 characters) in Polish. It references previous current reports and details the receipt of a final payment ($9.45 million USD) related to a prior acquisition (Curiosity Diagnostics). This payment was contingent upon the company repaying a loan to the European Investment Bank (EIB) and repurchasing warrants. This transaction involves the finalization of an acquisition/sale consideration and a related financing settlement. Since it is a specific announcement about receiving funds related to a corporate transaction (acquisition price finalization) and debt settlement, it most closely aligns with a Capital/Financing Update (CAP) or potentially a Regulatory Filing (RNS) if no better fit exists. Given the focus on receiving a large sum of money related to the acquisition price and settling financing obligations, 'CAP' (Capital/Financing Update) is the most appropriate specific category, as it details a significant cash flow event related to capital structure/financing terms.
2022-09-15 Polish
Otrzymanie potwierdzenie zapłaty płatności względem Europejskiego Banku Inwestycyjnego - Content (PL)
Capital/Financing Update Classification · 98% confidence The document text discusses the early repayment of financing (7 million EUR) provided by the European Investment Bank (EBI) and the repurchase of associated warrants. It explicitly mentions that the company will inform via a separate report about receiving payment from Bio-Rad Laboratories Inc. related to this transaction. The core subject is the termination of a financing agreement and related capital structure changes (warrants). This strongly aligns with the 'Capital/Financing Update' category, as it details the settlement and conclusion of a major financing arrangement. Given the short length (1331 chars) and the nature of the announcement (reporting on a completed financial event), it is a direct update rather than an announcement of a future report.
2022-09-12 Polish
Wystąpienie do EBI o przedterminową spłatę finansowania - Content (PL)
Capital/Financing Update Classification · 98% confidence The document text, written in Polish, discusses the company's decision to prepay the entirety of its financing from the European Investment Bank (EBI) following the sale of its subsidiary, Curiosity Diagnostics. It details the transaction amount, the repayment structure involving the principal, interest, fees, and the repurchase of warrants for a total payment of 2 million EUR. This action directly relates to the company's capital structure and financing agreements being terminated. This fits best under 'Capital/Financing Update' (CAP), as it is a significant event concerning the repayment and termination of a major financing agreement.
2022-08-05 Polish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.